SCHEMBL3763003

SCHEMBL3763003

Cc1cccc(C)c1C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 7/20 0.58
CHRM2 P08172 2/20 0.52
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
KCNH2 Q12809 1/20 0.50
HRH3 Q9Y5N1 1/20 0.46
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
PARP1 P09874 1/20 0.46
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RGS12 O14924 1/20 0.45
ACACB O00763 1/20 0.45
ACACA Q13085 1/20 0.45
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765908 0.88 CCR5 (0.45) CCR5CHRM2ALDH1A1KDM4EHRH3
SCHEMBL3772875 0.87 FNTA (0.51) CCR5ALDH1A1KDM4EHRH3MEN1
SCHEMBL3767212 0.87 HTT (0.56) CHRM2ALDH1A1KDM4EPARP1HTT
SCHEMBL3799209 0.87 NPC1 (0.52) CCR5ALDH1A1KDM4EHRH3MEN1
SCHEMBL3761223 0.86 ALDH1A1 (0.53) ALDH1A1KDM4EHRH3MEN1KMT2A
SCHEMBL3772561 0.86 ALDH1A1 (0.52) CCR5ALDH1A1KDM4EHRH3MEN1
SCHEMBL3770070 0.85 CHRM2 (0.51) CCR5CHRM2ALDH1A1KDM4EHRH3
SCHEMBL3780653 0.85 MGLL (0.49) CCR5ALDH1A1KDM4EHRH3MEN1
SCHEMBL3768032 0.85 KDM4E (0.52) ALDH1A1KDM4EMEN1KMT2AHTT
SCHEMBL3774250 0.84 MAPT (0.60) ALDH1A1KDM4EMEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CCR5 675/4885CHRM2 158/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.